Atkins H L, Mausner L F, Srivastava S C, Meinken G E, Straub R F, Cabahug C J, Weber D A, Wong C T, Sacker D F, Madajewicz S
Medical Department, Brookhaven National Laboratory, Upton, NY 11973.
Radiology. 1993 Jan;186(1):279-83. doi: 10.1148/radiology.186.1.7677974.
Tin-117 has certain physical characteristics (half-life of 13.6 days, low-energy-conversion electrons, gamma photon of 158.6 keV) that suggest that it may be a favorable agent for radionuclide therapy. It has been shown in animal models that Sn-117m in the chemical form Sn(4+)diethylenetriaminepentaacetic acid localizes selectively in bone. The authors therefore studied its whole-body distribution in 10 patients to obtain absorbed dose estimates for therapy. The results showed that more than 50% of the administered activity was absorbed in the bones of patients with metastatic carcinoma. Retention was determined primarily by radioactive decay. For adult men, the radiation absorbed dose estimate averaged 54.8 mGy/MBq (203 rad/mCi) to bone surfaces and 6.1 mGy/MBq (22.6 rad/mCi) to the red marrow. All other tissues received less than 1/10 of the dose received by red marrow. These results suggest that a clinical therapeutic trial should be attempted.
锡-117具有某些物理特性（半衰期为13.6天，低能转换电子，158.6keV的γ光子），这表明它可能是一种适合用于放射性核素治疗的药物。在动物模型中已表明，化学形式为Sn(4+)二乙烯三胺五乙酸的Sn-117m选择性地定位于骨骼中。因此，作者研究了其在10名患者体内的全身分布情况，以获得治疗的吸收剂量估计值。结果显示，转移性癌患者骨骼吸收了超过50%的给药活度。滞留主要由放射性衰变决定。对于成年男性，辐射吸收剂量估计平均为骨表面54.8mGy/MBq（203rad/mCi），红骨髓6.1mGy/MBq（22.6rad/mCi）。所有其他组织接受的剂量不到红骨髓的1/10。这些结果表明应尝试进行临床治疗试验。
